Skip to content

Sarilumab

    Brands

    DEA Class; Rx

    Common Brand Names; Kevzara

    • Interleukin Inhibitors; 
    • Monoclonal Antibodies; 
    • DMARDs, Immunomodulators

    Injectable interleukin-6 (IL-6) receptor antagonist
    Used for the treatment of moderate to severe rheumatoid arthritis in adults who have had an inadequate response or are intolerant to 1 or more DMARDs
    Boxed warning for increased risk of developing serious infections during therapy

    Indicated for adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to ≥1 disease-modifying antirheumatic drugs (DMARDs)

    Indicated for adults with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper

    Documented hypersensitivity to drug or inactive ingredients

    • ALT >ULN to ≤3 x ULN (38-43%)
    • AST >ULN to ≤3 x ULN (27-30%)
    • Neutropenia (7-10%)
    • ANC <1000/mm³ (4-6%)
    • Injection site erythema (4-5%)
    • Injection site pruritics (4-5%)
    • Upper respiratory tract infection (3-4%)
    • ALT >3x to 5x ULN (3-4%)
    • Urinary tract infection (3%)
    • Hypertriglyceridemia (1-3%)
    • Leukopenia (0.9-2%)

    Serious and sometimes fatal infections due to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens have been reported (see Black Box Warnings)

    GI perforations reported in clinical studies, primarily as complications of diverticulitis; GI perforation risk may be increased with concurrent diverticulitis or concomitant use of NSAIDs or corticosteroids

    Immunosuppression may result in an increased risk of malignancies

    Hypersensitivity reactions reported

    Not recommended with active hepatic disease or hepatic impairment

    Limited human data in pregnant women are not sufficient to inform drug-associated risk for major birth defects and miscarriage

    Unknown if distributed in human breast milk

    Adults

    200 mg/dose subcutaneously every 2 weeks; investigational doses of 400 mg IV have been used for COVID-19.

    Geriatric

    200 mg/dose subcutaneously every 2 weeks; investigational doses of 400 mg IV have been used for COVID-19.

    Adolescents

    Safety and efficacy have not been established.

    Children

    Safety and efficacy have not been established.

    Infants

    Safety and efficacy have not been established.

    sarilumab

    injectable solution (prefilled syringe)

    • 150mg/1.14mL
    • 200mg/1.14mL

    injectable solution (prefilled pen)

    • 150mg/1.14mL
    • 200mg/1.14mL